Treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women. Several recent studies demonstrated that the anticancer activity of bisphosphonates is not limited to bone, and can translate into a reduction in disease recurrence, including reductions in locoregional and distant metastases. In addition, bisphosphonates maintain bone health during adjuvant therapy; this may be especially important for women who are at high risk for fracture.
Introduction
Women with early-stage breast cancer generally have a favorable prognosis after fi rst-line treatment and surgical resection. Adding adjuvant therapy, especially for patients at high risk of recurrence, has been shown to improve outcomes, although such therapies may be associated with deteriorations in bone health [1] . When disease does recur in these patients, it is typically not at the primary tumor site but rather from cancer stem cells (CSCs) that metastasize to distant sites, such as the bone marrow [2] . In these sites, interactions between the CSCs and the normal tissue can create niches that facilitate cancer cell dormancy, allowing the CSCs to evade the cyto toxic or proapoptotic eff ects of therapies while maintaining their capacity to seed future metastases [3, 4] .
Fortunately, the multistep process required for cancer metastasis (for example, cancer cell mobilization, invasion into the vasculature, extravasation at distant sites, and angiogenesis) aff ords many opportunities for therapeutic intervention. Recent evidence has revealed that bisphosphonates, which have been investigated for protecting bone health in women receiving adjuvant therapy for breast cancer, can also have clinically meaningful anticancer eff ects. In the present article we review the available data indicating that bisphosphonates can reduce disease recurrence and can maintain bone health in women with breast cancer receiving adjuvant therapy.
Bone metastases and the bone marrow microenvironment
Bone is a common site for tumor metastasis, and some primary cancers appear to have an especially high propensity for metastasis to bone [5] . For example, the majority of patients with metastatic breast cancer or prostate cancer (approximately 75%) and a substantial proportion of patients with metastatic lung cancer (30 to 40%) will develop bone metastases [5] . Th e tendency of cancer cells to metastasize to bone is probably the end result of several factors including vascular pathways, the highly vascular nature of bone marrow (which increases the probability that cancer cells will be deposited in bone marrow capillaries), and molecular characteristics of the cancer cells that allow them to adapt to the bone marrow microenvironment [3, 4, 6] . In fact, breast cancer cells have been shown to adopt an osteoblast-like phenotype that may help them survive in the bone marrow [7] . Once in the bone marrow, CSCs may remain dormant for prolonged periods of time; however, the specifi c signals that control CSC dormancy and reactivation are currently not well understood [3] .
Several distinct niches in the bone marrow allow CSCs to interact with osteoblasts (endosteal niche) and hemato poietic stem cells (vascular niche), and these niches can shelter CSCs from adjuvant therapies [4] . Contact with integrins and exposure to bone-derived cytokines in the bone marrow can reduce proapoptotic signaling, and cell-adhesion molecules bind to receptors on cancer cells and promote drug resistance [3] . Dormant CSCs in the bone marrow (often referred to as disseminated tumor cells) are thought to be the source for distant metastasis to secondary sites, and may be reactivated by osteoclast-mediated release of bonederived growth factors. Indeed, a strong correlation between disseminated tumor cells in bone marrow or circulating CSCs in the bloodstream and an increased risk of disease recurrence (distant and locoregional) has been demonstrated in several studies [8] [9] [10] . In addition, many chemotherapy and endocrine therapy regimens increase bone turnover and release of growth factors, supporting CSC growth in the bone. Chemotherapy could therefore both lead to the death of and facilitate the survival (through dormancy in the bone marrow) of cancer cells.
Preventing bone metastases with bone-targeted therapies
Th e goal of adjuvant therapy for early-stage breast cancer is to reduce the risk of disease recurrence by targeting residual CSCs in the blood, regional lymph nodes, bone marrow, and ipsilateral and contralateral breast tissue. For most patients with endocrine-responsive breast cancer, surgical resection followed by adjuvant endocrine therapy produces excellent outcomes, and the risk of relapse is low. Th is approach may fall short in some women, however, primarily because quiescent CSCs in the bone marrow are resistant to cytotoxic chemotherapy or other targeted adjuvant therapies that are eff ective only against actively cycling cancer cells. For example, adjuvant endocrine therapy eff ectively reduces the proliferation of breast cancer cells by reducing circulating estrogen to barely detectable levels, or by blocking the action of estrogen (that is, tamoxifen). Reducing estrogen levels also increases bone turnover, however, which may render the bone marrow environment more conducive to the survival of CSCs. As a result, adjuvant therapies that target the microenvironment in addition to the CSCs may indirectly aff ect the ability of dormant cells to survive and reactivate, and therefore could be more successful.
Th ere is growing interest in using agents such as bisphosphonates to target CSCs in the bone microenvironment. Because bisphosphonates inhibit osteoclastmediated bone resorption, they reduce the release of bone-derived growth factors and other modulators necessary to promote cancer cell growth, diff erentiation, and tumor formation in bone. For example, the bisphosphonate zoledronic acid (ZOL) was shown in preclinical assays to prevent mesenchymal stem cells from secreting factors (RANTES and IL-6) involved in breast cancer migration and proliferation [11] . Adding ZOL also sensitizes colon CSCs to γδ T-cell-mediated cytotoxicity [12] . In addition, data from multiple clinical trials suggest that bone-targeted therapy not only renders the bone a less hospitable environment, but may also directly aff ect the viability of CSCs. Recently, clinical trials in women with breast cancer suggested that bisphosphonates can improve outcomes by targeting both the seed (the CSCs) and the soil (the bone marrow microenvironment) [13] [14] [15] . Indeed, ZOL was shown to reduce disseminated tumor cells in four phase II trials in women with breast cancer (total n = 435) [16] [17] [18] [19] [20] [21] . In addition, investigational therapies -such as receptor activator of NF-κB ligand inhibitors, Src inhibitors, cathepsin K inhibitors, and integrin inhibitors -may render the bone microenvironment less favorable for cancer cell growth; however, their effi cacy has not been established clinically. Th e unique potential of bisphosphonates to prevent bone metastases may be that they have both direct and indirect anticancer activity (targeting the cancer cells and bone).
Bisphosphonate adjuvant clinical trials
Th e potential anticancer activity of adjuvant bisphosphonate therapy for reducing disease recurrence has been examined in several clinical trials in women with early-stage breast cancer. Data from two clinical trials (n = 1,359) indicated that patients who received oral clodronate (1,600 mg/day for 2 years) experienced a delay in developing bone metastases and showed improved disease-free survival and overall survival [22, 23] . Conversely, another trial (n = 299) of oral clodronate (1,600 mg/day for 3 years) found no signifi cant survival benefi t; however, imbalances in the clodronate and control groups may have contributed to the lack of anticancer eff ect in this trial [24, 25] . Although two out of the three trials showed a benefi t with adjuvant clodronate, a meta-analysis of data from breast cancer trials was unable to detect a signifi cant overall survival benefi t or a signifi cant reduction in bone metastases (Figure 1) [23, 24, 26, 27] . Data from a trial in patients receiving adjuvant chemotherapy for breast cancer (n = 953) suggested that oral pamidronate (150 mg twice daily for 4 years) does not improve disease outcomes in patients in this setting [28] . Oral pamidronate may not, however, be as effi cacious as the approved intravenous formulation.
Although trials of oral bisphosphonates (clodronate and pamidronate) have produced variable results, recent clinical trials of intravenous ZOL have demonstrated somewhat more consistent anticancer benefi ts in the adjuvant setting. In the ABCSG-12 trial (n = 1,803), premenopausal women with endocrine-responsive breast cancer received goserelin and were randomized to tamoxifen or anastrozole, with or without ZOL (4 mg every 6 months) [15] . After a median follow-up of 48 months, ZOL signifi cantly reduced the risk of diseasefree survival events by 36% (hazard ratio = 0.64; P = 0.01) (Figure 2) [14, 15, 29] , and produced a trend toward improved overall survival compared with patients who received endocrine therapy without ZOL. Overall, adding ZOL to endocrine therapy reduced the number of locoregional, contralateral, and distant recurrences (at bone and nonbone sites). At 62 months' median followup, more than 2 years after treatment ended, ZOL continued to reduce the risk of disease-free survival events by 32% (hazard ratio = 0.68; P = 0.009), with similar risk reductions in each of the endocrine therapy arms (Figure 2) [14, 15, 29] . Similar anticancer eff ects of ZOL were also observed in a trial in postmenopausal women with early breast cancer receiving adjuvant endocrine therapy. Among women enrolled in the ZO-FAST study (n = 1,065), patients who received upfront ZOL had fewer disease recurrence events at all sites, and ZOL reduced the relative risk of disease-free survival events by 41% (hazard ratio = 0.59; P = 0.0314) compared with patients in the delayed-ZOL group at 36 months (Figure 2) [14, 15, 29] .
In addition to the anticancer eff ects observed in adjuvant breast cancer trials, an exploratory analysis of patients with stage II/III breast cancer who received neoadjuvant therapy with or without ZOL (n = 205) in the AZURE trial (total n = 3,360) found that ZOL had anticancer eff ects on the primary tumor [13] . In this substudy, ZOL reduced residual invasive tumor size by 44% (15.5 mm vs. 27.4 mm for chemotherapy alone; P = 0.006) and improved complete pathologic response nearly twofold in patients who received ZOL combined with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone.
Additional data on the potential anticancer benefi ts of antiresorptive agents have emerged from the benign osteoporosis setting. In three recent large database studies (total n = 164,718), healthy postmenopausal women receiving oral bisphosphonates to treat osteoporosis were found to have a signifi cantly reduced risk of breast cancer compared with women who did not receive bisphosphonates, an eff ect that appeared to persist even after indirectly compensating for likely diff erences in bone mineral density between users and nonusers of bisphosphonates [30] [31] [32] . Th ese data support the anticancer benefi ts of bisphosphonates observed in women receiving adjuvant breast cancer therapy, and suggest that the anticancer benefi ts of bisphosphonate therapy may be clinically meaningful even early in the disease course, before the cancer has reached a detectable level.
Taken together, these data are intriguing and suggest that bisphosphonates can have anticancer eff ects on the primary tumor and on disseminated CSCs. Several ongoing clinical trials of bisphosphonates in the neoadjuvant and adjuvant settings will further defi ne the effi cacy of these agents in the breast cancer setting.
Maintaining bone health in women with early breast cancer
It is well understood that many therapies for women with early-stage breast cancer can have negative eff ects on bone and may result in signifi cant bone loss -that is, low bone mineral density (BMD) -within the fi rst 1 to 2 years of therapy. In premenopausal women, cytotoxic chemotherapy can induce premature menopause and, in women with hormone-responsive breast cancer, ovarian suppression and endocrine therapy can cause rapid bone loss [33, 34] . Similarly, adjuvant aromatase inhibitor therapy is associated with signifi cant bone loss and increased fracture risk in postmenopausal women compared with women who received tamoxifen [35] [36] [37] [38] . At diagnosis, women with breast cancer may already have several additional risk factors, unrelated to bone loss from breast cancer therapies, which add to their fracture risk. Th ese baseline risk factors may include age (>65 years), a history of fragility fracture after the age of 50, body mass index <20 kg/m 2 , family history of osteoporosis, current or history of smoking, and oral corticosteroid use >6 months [1] . Each of these risk factors has been shown to increase a woman's fracture risk independent of BMD and is important in determining her overall fracture risk. Th e bone health of women with early breast cancer is often under assault by several factors; it is therefore of great importance to proactively address these risks through a combination of diet and lifestyle changes, as well as through pharmaceutical intervention when needed.
Several recent clinical trials examined the use of bisphosphonates to prevent bone loss associated with adjuvant endocrine therapy in premenopausal and postmenopausal women with early-stage breast cancer. Results from early trials of oral bisphosphonates demonstrated that these agents have only limited effi cacy for preventing cancer treatment-induced bone loss and may be associated with poor patient compliance for treatment regimens outside the clinical trial setting. In the recent small-scale ARIBON study in patients (n = 50) with early breast cancer and osteopenia receiving anastrozole (1 mg/day), however, monthly oral ibandronate (150 mg) improved lumbar spine BMD compared with baseline by approxi mately 3% after 1 and 2 years of therapy [39] . In two other studies in post meno pausal women receiving anastrozole (1 mg/day) for preven tion (n = 59) or for treatment (n = 118) of endocrineresponsive breast cancer, weekly oral risedro nate improved lumbar spine and/or hip BMD compared with baseline [40, 41] . Additionally, the SABRE trial showed that oral risedronate (35 mg/week) inhibited lumbar spine and total hip BMD loss for up to 24 months of treatment in postmenopausal women with a moderate to high risk of fragility fracture receiving anastrozole (1 mg/day) [42] .
Intravenous bisphosphonates (for example, ZOL) can also prevent bone loss associated with adjuvant endocrine therapy in premenopausal and post meno pausal women. In the ABCSG-12 trial bone substudy (n = 404) in premenopausal women, adding ZOL maintained stable BMD during 3 years of endocrine therapy, and increased BMD for at least 2 years after treatment completion [43] . In four similarly designed trials (total n = 2,240), upfront ZOL (4 mg every 6 months) signifi cantly increased BMD in postmeno pausal women during adjuvant letrozole therapy com pared with baseline [14, [44] [45] [46] . Across all studies, the overall percentage diff erence in BMD between the upfront-ZOL and delayed-ZOL groups continued to increase for up to 5 years [47] . Although these studies were not powered to detect between-group diff erences in fracture incidence, fewer fractures occurred in women who received upfront ZOL.
Current oncology guidelines for addressing bone health in women receiving adjuvant endocrine therapy for early breast cancer rely mainly on BMD T scores to determine the fracture risk and to guide treatment. Th e American Society of Clinical Oncology guidelines published in 2003 rely on BMD as an indicator, and only recommend antiresorptive therapy with bisphosphonates in women who are osteoporotic [48] . Recently updated osteoporosis guidelines from the World Health Organization and the National Osteoporosis Foundation use BMD in addition to risk factors as indicators (family history of hip fracture; personal history of fracture, rheumatoid arthritis, or secondary osteoporosis; glucocorticoid use; smoking; alcohol intake) to decide when to initiate bisphosphonate therapy. Although the recently developed FRAX algorithm (used by the World Health Organization and the National Osteoporosis Foundation) can estimate fracture risk in healthy postmenopausal women, it is not appropriate for women with breast cancer because it does not adequately assess the fracture risk associated Horizontal lines, 95% confi dence intervals. ZOL, zoledronic acid. Data from Gnant and colleagues [15, 29] and Eidtmann and colleagues [14] .
Gnant and Hadji Breast Cancer Research 2010, 12:216 http://breast-cancer-research.com/content/12/6/216 with breast cancer therapy. In addition, BMD assessment may not be routinely available for breast cancer patients.
As the importance of clinical risk factors for fracture has become increasingly apparent, emerging guidance from oncology experts has evolved to include an overall fracture risk assessment using clinical risk factors and BMD when available. For example, experts from the UK recommend using risk factors, age, and BMD to determine whom to treat [49] . Similarly, a group from Belgium recommends using specifi c risk factors for osteo porotic fractures (age, prior fragility fracture, medication use, or disease or medical condition that is associated with low bone mass or bone loss) to assess fracture risk [50] . Finally, an international panel of experts recommends using identifi ed risk factors (T score <1.5, age >65 years, body mass index <20 kg/m 2 , family history of hip fracture, personal history of fragility fracture after age 50, oral corticosteroid use >6 months, and smoking) with or without BMD (Figure 3) [1] . Although the details of the algorithms used to assess fracture risk in women with breast cancer vary slightly between expert groups, the overall consensus seems to favor a comprehensive fracture risk evaluation to deter mine who should receive antiresorptive therapy. Combining aromatase inhibitor therapy with bisphosphonate treatment in women with a high risk of fracture also appears to perhaps allow patients to gain the anticancer benefi t of aromatase inhibitor therapy without the negative eff ects on bone health.
Conclusions
Th e available evidence clearly indicates that bone health is an important consideration when initiating therapy for women with early breast cancer. Recent clinical guidelines have improved identifi cation of patients who would benefi t from adjuvant bisphosphonate therapy in this setting. In addition to observed benefi cial eff ects on BMD, recent data suggest there is also a potential for disease recurrence advantages with bisphosphonates. Based on the anticancer activity of bisphosphonates for reducing disease recurrence in the adjuvant breast cancer setting, as well as the provocative fi nding of reduced breast cancer incidence in the osteoporosis trials, there is increasing evidence that beginning bisphosphonate therapy early in the disease course may provide the greatest benefi ts. a If patients experience an annual decrease in bone mineral density (BMD) ≥5% (using the same dual-energy X-ray absorptiometry machine), secondary causes of bone loss such as vitamin D defi ciency should be evaluated and bisphosphonate therapy considered. Use the lowest T score from three sites. BMI, body mass index. Reprinted from [1] with permission from the European Society for Medical Oncology.
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